MobiHealthNews discusses two recent Canadian studies reaching the conclusion that Type 2 diabetics not taking insulin receive only modest benefit from daily monitoring, and could reduce testing to once or twice a week. The major conclusions are focused on cost savings, with daily testing considered to be ‘ineffective use of health resources.’ In other words, it’s money, not the benefit of self-monitoring which this editor believes would be valuable for non-insulin controlled diabetics. The additional irony is the increasing prevalence of diabetes in Western countries has become a major mover of mHealth. Article. Science Daily report.